Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala.
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
/ epidemiology
Chemoradiotherapy
Female
Guatemala
/ epidemiology
Humans
Lost to Follow-Up
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Patient Acceptance of Health Care
/ psychology
Patient Compliance
/ psychology
Retrospective Studies
Treatment Outcome
Uterine Cervical Neoplasms
/ epidemiology
Young Adult
Journal
Journal of global oncology
ISSN: 2378-9506
Titre abrégé: J Glob Oncol
Pays: United States
ID NLM: 101674751
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
entrez:
9
5
2019
pubmed:
9
5
2019
medline:
23
7
2020
Statut:
ppublish
Résumé
Despite being the only hospital to provide comprehensive cervical cancer treatment to many medically underserved Guatemalan women, no assessment of the cervical cancer patient population at the Guatemala Cancer Institute has been performed. To understand the demographics of the patient population, their treatment outcomes, and access to care, we sought to assess treatment compliance of patients with cervical cancer at the Guatemala Cancer Institute and its effects on patient outcomes. A retrospective chart review was conducted of patients with cervical cancer between 2005 and 2007 and assessed for follow-up through December 2015. Demographics and clinical characteristics were tabulated. A Kaplan-Meier curve to model compliance was generated. Ninety-two patients with invasive cancer were analyzed. Most presented with squamous cell carcinoma (73%) and at locally advanced stages (IIB, 51%; IIIB, 33%). Most (75 of 92, 81.5%) initiated treatment after diagnosis, but 18.5% (17 of 92) were lost to follow-up before treatment initiation. For treatment, 97% received external beam radiation, 84% brachytherapy, and 4% concomitant chemotherapy. Nearly 20% of patients were lost to follow-up in the first 6 months and 65% in the first 5 years. Of the 67 patients who completed treatment, only 15 (16% of the initial cohort) were diagnosed with a recurrence. No deaths were recorded. The low recurrence rate and no documented deaths suggest a correlation with the low compliance rate and poor follow-up. This finding highlights the need to examine more fully the barriers to compliance and access to care among this population to optimize the treatment of cervical cancer.
Identifiants
pubmed: 31067142
doi: 10.1200/JGO.18.00243
pmc: PMC6550059
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-5Subventions
Organisme : NCI NIH HHS
ID : T32 CA190194
Pays : United States
Références
Lancet Oncol. 2015 Sep;16(10):1143
pubmed: 26419348
Ann Surg Oncol. 2015 Mar;22(3):728-33
pubmed: 25605513
Front Oncol. 2015 Jan 22;4:380
pubmed: 25657930
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Int J Radiat Oncol Biol Phys. 1992;24(2):197-204
pubmed: 1526855
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Oncol (R Coll Radiol). 2015 Feb;27(2):107-14
pubmed: 25455407
Int J Gynecol Cancer. 2015 Nov;25(9):1669-76
pubmed: 26270123
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
Cancer. 2016 Feb 15;122(4):502-14
pubmed: 26670695
Reprod Health. 2015 Jun 17;12:56
pubmed: 26081494